Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588462 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2CSNK2A1KDM4E | |
| SCHEMBL20551182 | 0.98 | HCRTR1 (0.50) | HCRTR1HCRTR2CSNK2A1KDM4E | |
| SCHEMBL20550637 | 0.98 | HCRTR1 (0.50) | HCRTR1HCRTR2CSNK2A1KDM4E | |
| SCHEMBL28719003 | 0.89 | HCRTR1 (0.43) | HCRTR1HCRTR2CSNK2A1 | |
| SCHEMBL27854226 | 0.88 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL7913811 | 0.86 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL14843975 | 0.86 | CSNK2A1 (0.46) | HCRTR1HCRTR2CSNK2A1KDM4E | |
| SCHEMBL20550656 | 0.85 | CSNK2A1 (0.44) | HCRTR1HCRTR2CSNK2A1KDM4E | |
| SCHEMBL20714330 | 0.85 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL2306774 | 0.85 | HCRTR1 (0.50) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| CN-111943945-B | Suvorexant intermediate and preparation method thereof | 上海应用技术大学 | 2022-07-12 | — | — | CN | claimed |
| EP-3412665-B1 | SUVOREXANT INTERMEDIATES AND PREPARATION METHODS THEREOF | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2021-03-03 | — | — | EP | claimed |
| CN-111943945-A | Suvorexant intermediate and preparation method thereof | 上海应用技术大学 | 2020-11-17 | — | — | CN | claimed |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-14 | — | — | US | claimed |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-07 | — | — | US | claimed |
| EP-3412665-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-12-12 | — | — | EP | claimed |
| CN-103923068-A | Compound for preparing suvorexant and preparation method thereof | WUHAN JIAYU TECHNOLOGY CO LTD | 2014-07-16 | — | — | CN | claimed |
| CN-103012293-A | Synthetic method for anti-sleeplessness medicine MK-4305 intermediate | UNIV TONGJI | 2013-04-03 | — | — | CN | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12583841-B2 | Tetrahydropyrrolocyclic compound and application thereof | Breakthrough Pharmaceuticals Inc. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2008-06-05 | — | — | US | disclosed |
| WO-2008008517-A2 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008517-A2 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008518-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | HCRTR1 2/4885HCRTR2 1/4885CSNK2A1 3485/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | HCRTR1 130/4885HCRTR2 124/4885CSNK2A1 1260/4885 |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | COMT, KMO, CYP4B1 | HCRTR1 62/4885HCRTR2 28/4885CSNK2A1 1270/4885 |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | COMT, KMO, CYP4B1 | HCRTR1 62/4885HCRTR2 28/4885CSNK2A1 1270/4885 |
| US-12583841-B2 | Tetrahydropyrrolocyclic compound and application thereof | HCRTR2, HCRTR1, CRHR2 | HCRTR1 2/4885HCRTR2 1/4885CSNK2A1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.